Stocks and Investing Stocks and Investing
Wed, February 8, 2023

Graig Suvannavejh Maintained (BTAI) at Strong Buy with Increased Target to $38 on, Feb 8th, 2023


Published on 2024-10-28 01:27:29 - WOPRAI, Graig Suvannavejh
  Print publication without navigation


Graig Suvannavejh of Mizuho, Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Increased Target from $24 to $38 on, Feb 8th, 2023.

Graig has made no other calls on BTAI in the last 4 months.



There are 4 other peers that have a rating on BTAI. Out of the 4 peers that are also analyzing BTAI, 1 agrees with Graig's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Corinne Jenkins of "Goldman Sachs" Maintained at Hold with Increased Target to $26 on, Thursday, January 26th, 2023


These are the ratings of the 3 analyists that currently disagree with Graig


  • Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $73 on, Tuesday, January 3rd, 2023
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $76 on, Friday, November 11th, 2022
  • Yatin Suneja of "Guggenheim" Maintained at Strong Buy with Decreased Target to $25 on, Friday, November 11th, 2022

Contributing Sources